Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis

被引:1
作者
Pohl, Sarah B. [1 ]
Engelbertz, Christiane [1 ]
Reinecke, Holger [1 ]
Malyar, Nasser M. [1 ]
Meyborg, Matthias [1 ]
Brix, Tobias J. [2 ]
Varghese, Julian [2 ]
Gebauer, Katrin [1 ,3 ]
机构
[1] Univ Hosp Muenster, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Heart Failure, Cardiol, D-48149 Munster, Germany
[2] Univ Munster, Inst Med Informat, D-48149 Munster, Germany
[3] Univ Hosp Muenster, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Heart Failure, Albert Schweitzer Campus 1,Geb A1, D-48149 Munster, Germany
关键词
Cholesterol; Statin; Hyperchole-; sterolemia; Lipid-lowering therapy; Secondary prevention; Ezetimibe; CORONARY-HEART-DISEASE; STATIN; METAANALYSIS; MANAGEMENT; EFFICACY; PLACEBO; TRIAL;
D O I
10.1016/j.numecd.2024.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in Europe. Although the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidaemias claim a target low-density lipoprote in cholesterol (LDL-C) value of <55 mg/dL for very high-risk patients by use of lipidlowering therapy (LLT) and lifestyle adaptations, the target level achievement is not satisfactory. We examined LLT use in ASCVD patients exceeding LDL-C target levels at admission and its adaptations at discharge. Methods and results: Between January 2017 and February 2020, 1091 patients with LDL-C >100 mg/dL and ASCVD defined as diagnosis of angina pectoris (AP, n = 179), acute myocardial infarction (AMI, n = 317), chronic ischemic heart disease (CHD, n = 195), or peripheral artery disease (PAD, n = 400) were extracted from hospital records. LLT use on admission and discharge as well as recommendations on lifestyle and nutrition were analysed. On admission, 51% of the patients were not taking LLT. At discharge, 91% were prescribed statins and 87% were advised on lifestyle adaptation and/or pharmacological treatment. Highintensity statin use at discharge was present in 63% of the AP-group, 92% of the AMI-group, 62% of the CHD-group and 71% of the PAD-group. Ezetimibe was present in 16% and proprotein convertase subtilisin/kexin 9 inhibitors (PCSK9i) in 1%. However, of those on high-intensity statin, 25% remained on insufficient statin dosage. Conclusion: Switch to high-intensity statins and use of ezetimibe and PCSK9i was low in chronic ASCVD patients. Even though statin intake was high in high-risk patients, target levels were still not reached. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 50 条
[11]   Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial [J].
Lee, Jung-Hee ;
Ahn, Sung Gyun ;
Jeon, Ho Sung ;
Lee, Jun-Won ;
Youn, Young Jin ;
Lee, Yong-Joon ;
Lee, Seung-Jun ;
Hong, Sung-Jin ;
Ahn, Chul-Min ;
Ko, Young-Guk ;
Kim, Jung-Sun ;
Choi, Donghoon ;
Hong, Myeong-Ki ;
Jang, Yangsoo ;
Kim, Byeong-Keuk .
JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (06) :e905-e914
[12]   Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease [J].
Karalis, Dean G. .
CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (06) :252-258
[13]   Clinical Significance of Mild Lipid-Lowering by Statins for Prevention of Cardiovascular Disease in Japanese High-Risk Patients [J].
Miyazaki, Tetsuro ;
Daida, Hiroyuki .
CIRCULATION JOURNAL, 2010, 74 (04) :630-631
[14]   Combination lipid-lowering therapy as first-line strategy in very high-risk patients [J].
Ray, Kausik K. ;
Reeskamp, Laurens F. ;
Laufs, Ulrich ;
Banach, Maciej ;
Mach, Francois ;
Tokgozoglu, Lale S. ;
Connolly, Derek L. ;
Gerrits, Anja J. ;
Stroes, Erik S. G. ;
Masana, Luis ;
Kastelein, John J. P. .
EUROPEAN HEART JOURNAL, 2022, 43 (08) :830-833
[15]   Persistent gaps in the implementation of lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease: A French nationwide study [J].
Wargny, Matthieu ;
Goronflot, Thomas ;
Piriou, Pierre-Guillaume ;
Pouriel, Mathilde ;
Bastien, Alexandre ;
Prax, Julie ;
Leux, Christophe ;
Riche, Valery-Pierre ;
Trochu, Jean-Noel ;
Beliard, Sophie ;
Costa, Nadege ;
Ferrieres, Jean ;
Duret, Stephanie ;
Cariou, Bertrand .
DIABETES & METABOLISM, 2025, 51 (03)
[16]   Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk [J].
Avogaro, Angelo ;
Buzzetti, Raffaella ;
Candido, Riccardo ;
De Cosmo, Salvatore ;
Notarianni, Lucia ;
Consolo, Eleonora ;
Luciano, Myriam .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 222
[17]   The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia [J].
Penson, Peter E. ;
Banach, Maciej .
CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (11)
[18]   Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy [J].
Citarella, Anna ;
Cammarota, Simona ;
Bernardi, Francesca Futura ;
Caliendo, Luigi ;
D'Andrea, Antonello ;
Fimiani, Biagio ;
Fogliasecca, Marianna ;
Pacella, Daniela ;
Pagnotta, Rita ;
Trama, Ugo ;
Zito, Giovanni Battista ;
Cillo, Mariarosaria ;
Vercellone, Adriano .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
[19]   New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease [J].
Burger, Achim Leo ;
Pogran, Edita ;
Muthspiel, Marie ;
Kaufmann, Christoph Clemens ;
Jaeger, Bernhard ;
Huber, Kurt .
BIOMEDICINES, 2022, 10 (05)
[20]   How to overcome barriers to the implementation of prevention and treatment strategies for atherosclerotic cardiovascular disease through lipid-lowering therapy [J].
Arca, Marcello ;
Averna, Maurizio ;
Borghi, Claudio ;
Lettino, Maddalena ;
Filardi, Pasquale Perrone ;
Alberti, Antonia ;
Bilato, Claudio ;
Calabro, Paolo ;
Carubbi, Francesca ;
Ciccone, Marco Matteo ;
Cipollone, Francesco ;
Citroni, Nadia ;
De Luca, Leonardo ;
Giaccari, Andrea ;
Iannuzzo, Gabriella ;
Maloberti, Alessandro ;
Marcucci, Rossella ;
Spinazzola, Pasquale Pignatelli ;
Pirro, Matteo ;
Pisciotta, Livia ;
Sarullo, Filippo ;
Sciacqua, Angela ;
Suppressa, Patrizia ;
Varbella, Ferdinando ;
Werba, Jose Pablo ;
Zambon, Alberto .
GIORNALE ITALIANO DI CARDIOLOGIA, 2023, 24 (10) :770-780